1 completed, 1 not yet recruiting, 1 terminated. 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 1, Not yet recruiting 1, Terminated 1 |
Follow olaparib: new trials by email Literature Review of olaparib trials Research Report on olaparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel Iparomlimab and tuvonralimab combined with olaparib and paclitaxel - Triple Negative Breast Cancer (TNBC) | Not applicable | Not yet recruiting | Harbin Medical University | 20 | 2025-12-30 | 2025-09-23 |
| Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study Trametinib, Cobimetinib, Binimetinib - Cancer | Not applicable | Terminated | Peter MacCallum Cancer Centre, Australia | 3 | 2021-09-23 | 2023-05-10 |
| A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer Cediranib, Olaparib - Ovarian Cancer | Not applicable | Completed | University Health Network, Toronto | 34 | 2016-04-29 | 2022-05-09 |
Neoplasms (1) · Ovarian Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Harbin Medical University (1) · Peter MacCallum Cancer Centre, Australia (1) · University Health Network, Toronto (1)
Australia (1) · Canada (1)
Amit Oza, M.D. (1) · Stephen Luen, MBBS (1)